Objective: Tumours in the adrenocortex are common human tumours. Malignancy is however, rare, the yearly incidence being 0.5-2 per million inhabitants, but associated with a very aggressive behaviour. Adrenocortical tumours are often associated with altered hormone production with a variety of clinical symptoms. The aggressiveness of carcinomas together with the high frequency of adenomas calls for a deeper understanding of the underlying biological mechanisms and an improvement of the diagnostic possibilities. Methods: Microarray gene expression analysis was performed in tumours of adrenocortex with emphasis on malignancy as well as hormonal activity. The sample set consisted of 17 adenomas, 11 carcinomas and 4 histological normal adrenocortexes. RNA from these was hybridised according to a reference design on microarrays harbouring 29 760 human cDNA clones. Confirmation was performed with quantitative real time-PCR and western blot analysis. Results: Unsupervised clustering to reveal relationships between samples based on the entire gene expression profile resulted in two subclusters; carcinomas and non-cancer specimens. A large number of genes were accordingly found to be differentially expressed comparing carcinomas to adenomas. Among these were IGF2, FGFR1 and FGFR4 in growth factor signalling the most predominant and also the USP4, UBE2C and UFD1L in the ubiquitin-proteasome pathway. Moreover, two subgroups of carcinomas were identified with different survival outcome, suggesting that survival prediction can be made on the basis of gene expression profiles. Regarding adenomas with aldosterone overproduction, OSBP and VEGFB were among the most up-regulated genes compared with the other samples. Conclusions: Adrenocortical carcinomas are associated with a distinct molecular signature apparent in their gene expression profiles. Differentially expressed genes were identified associated with malignancy, survival as well as hormonal activity providing a resource of candidate genes for an exploration of possible drug targets and diagnostic and prognostic markers.
Introduction
Adrenocortical tumours have a relatively high prevalence in the general population of up to 9% in autopsy studies (1, 2) . However, malignancy is rare, the yearly incidence being 0.5-2 per million people, but with only 12 months mean survival time for patients with nonresectable cancers (3) (4) (5) (6) (7) . The aggressiveness of carcinomas together with the high frequency of adenomas calls for a deeper understanding of the underlying biological mechanisms and an improvement of the diagnostic possibilities.
Most adrenocortical tumours are detected incidentally with computed tomography (CT) or magnetic resonance imaging (MRI), although some give clinical signs, associated with the specific hormone over-expressed, e.g. aldosterone or cortisol. Adenoma development sometimes leads to overproduction of one or a mixture of these hormones. Aldosterone producing tumours (aldosteronomas) causes hypertension, while cortisol overproduction induces Cushing's syndrome. Adrenocortical carcinomas are often large and may therefore be present with abdominal pain and weight loss, with or without a mixture of the different hormones. The hormonal profiles associated with adrenocortical tumours makes hormonal screening an appealing clinical approach for diagnosis and analyses of steroid profiles may also contribute to set the malignant diagnosis. As a result of the recent advances in the bioimaging field and the more frequent use of CT and MRI, the number of detected tumours is increasing. The main indication for adrenalectomy of tumours without hormone overproduction is the size of the tumour based on CT and MRI. All tumours with a diameter larger than 4 cm are, in most countries, recommended to be surgically resected (8) . Development of adrenocortical carcinoma is not well characterised. Comparative hybridisation studies and allelotyping have shown that the number of genetic alterations increases with tumour size as a sign of an overall altered genetic stability in the malignant tumours (4, 5, 9) . The most common genetic aberrations are gains on chromosome 4 and 5 and losses on chromosome 11 and 17. Also in benign tumours gains have been observed, on the long arm of chromosome 4 (10) . Mutations of TP53 as well as over-expression of IGF2 due to CpG island demethylation are shared features of malignant tumours (11) .
Tumour classification based on microarray gene expression data has demonstrated promising results for numerous cancer types with potential clinical applications (12) (13) (14) (15) . There are principally two categories of classification: unsupervised and supervised, which are used for two different purposes. Unsupervised classification is mainly used for exploratory analysis, clustering tumours into groups based on similarities of gene expression profiles. If the resulting clusters have concordance with diagnosis or outcome the unsupervised clustering method can be used as a diagnostic and prognostic tool. Supervised classification on the other hand is always performed to create a diagnostic tool, which is to be used for discrimination of new data. Development of the classifier is based on prior information of how tumour types are connected to the appearance of gene expression profiles. This can be obtained by performing microarray analysis on samples with well-established diagnosis and with long follow-up.
In a previous microarray study (16) , we have shown that adrenocortical carcinomas have gene expression signatures that can be distinguished from adenomas. In this report the sample size has been increased and we further analyse transcriptional differences in subtypes of hormone producing adrenocortical tumours, incidentalomas and normal adrenal cortex. Furthermore, based on the gene expression profiles, we suggest candidates for potential markers for the diagnosis of adrenocortical carcinoma. We also show that the carcinoma tumours cluster into two separate groups correlated to the survival time.
Methods

Tissue samples
This study included 4 normal adrenal cortex samples and all together 28 sporadic adrenocortical tumours; 4 aldosteronomas, 5 cortisol producing adenomas (here denoted as Cushing in figures and tables), 8 incidentalomas and 11 adrenocortical carcinomas. Cases with incidentaloma did not exhibit hormonal overproduction as determined by urinary and serum measurements. A subset of the tumours, 7 carcinomas and 13 adenomas, were included in a previous study and the data has been integrated into this extended study (16) . All cases were selected from a cohort of 250 patients operated at the Karolinska University Hospital from 1986 to 2004 as described (16) . Excluded cases were those with adrenal hyperplasia or tumours from the adrenal medulla. The tumour tissue analysed contained more than 70% tumour cells. Every patient had a clinical follow-up for at least 1.5 years. Diagnostic criteria for malignancy were vascular invasion, invasion of surrounding organs and/or presence of distant metastasis. In cases where these criteria were not fulfilled the histopathological criteria proposed by Weiss was used (17) . Cases with high nuclear grade, increased mitotic figures and tumour necrosis were suspected to be malignant. The appearance of metastasis at follow-up, or recurrences further facilitated the establishment of a malignant diagnosis. Normal adrenal cortex samples were obtained from patients undergoing nephrectomy for other reasons and used as normal references in the RNA analysis. Matching normal adrenal cortex was obtained from four of the cases for western blot analysis. The clinical and tumour characteristics are shown in Table 1 . The samples were obtained with informed consent and the study of the tissue material was approved by the Ethical Committee of the Karolinska University Hospital.
RNA extraction
A fresh frozen piece of w100 mg was used for RNA extraction. Representative sections from all specimens were subjected to histopathological evaluation for tumour representativity. Total RNA was extracted using Qiagen mini and midi preps kits for RNA purification. RNA quantity and quality were assessed by an ND-1000 spectrophotometer (Nanodrop, San Francisco, CA, USA) and 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Design of microarray experiments
We used a reference design where each sample was hybridised in duplicates. Tumour samples were labelled with Cy5 and hybridised with Cy3 labelled commercially available Universal Human Reference RNA (UHRR; Stratagene, La Jolla, CA, USA).
Microarray production
In-house manufactured cDNA microarrays with 29 760 cDNA fragments representing 18 953 unique human UniGene IDs were used. The cDNA clones originate from the sequence verified human clone collection, 97001.V, plates 1-310 (Research Genetics Inc., Huntsville, AL, USA). The microarrays were spotted onto Ultra GAPS slides (Corning, Lowell, MA, USA) with a Qarray2 arrayer with 48 K2805 pins (Genetix, Hampshire, UK). The complete protocols for preparation of clones and printing together with a complete gene list can be found at www.ktharray.se and at ArrayExpress (A-MEXP-114).
Target labelling
First strand cDNA target was generated by RT of 10 mg of total RNA in a 30 ml reaction using 5 mg random hexamers (Operon), first-strand buffer (50 mM TrisHCl, pH 8.3, 75 mM KCl, 3 mM MgCl 2 ), 0.01 mM dithiothreitol (DTT), 400 units Superscript III (Invitrogen), 2 mM d(A/G/C)TPs, 1.6 mM dTTP (Amersham Biosciences) and 0.4 mM aminoallyl-dUTP (SigmaAldrich). Secondary structures of RNA and primers were removed at 70 8C during 10 min followed by 2 min of incubation on ice for primer annealing before addition of the other reaction components. cDNA synthesis was performed for 2 h at 42 8C and terminated by addition of EDTA. The RNA was hydrolysed in NaOH during 15 min incubation at 70 8C followed by neutralisation with HCl (final concentrations 20, 150 and 150 mM, respectively). The cDNA was purified using MinElute spin columns (Qiagen) with the provided wash buffer replaced by 80% ethanol and the elution buffer by 100 mM NaHCO 3 , pH 9.0. Monofunctional NHS-ester Cy3 or Cy5 fluorophores (Amersham Biosciences) were coupled to the amino-allyl groups during a 30-min incubation at room temperature after which unincorporated ester groups were inactivated through a hydroxylamine treatment (final concentration of 730 mM). The labelling reactions were purified using MinElute spin columns. The complete protocol for target labelling can be downloaded from www.ktharray.se. Extraction and labelling quality/quantity were assessed with an ND-1000 spectrophotometer (Nanodrop).
Hybridisations and scanning
The slides were prehybridised in 5!SSC, 0.1% SDS and 1% BSA (Sigma-Aldrich) for 30 min in 42 8C. The hybridisation buffer contained 50% formamide, 5!SSC, 0.1% SDS, 10 mg COT-1 DNA (Invitrogen) and 5 mg tRNA (Sigma-Aldrich). After hybridisations in chambers (Corning) for 18 h at 42 8C the arrays were washed according to Corning's recommendations and scanned at 532 and 635 nm with 10-mm resolution using a G2565BA DNA microarray scanner (Agilent Technologies).
Data analysis
Image analysis was performed in GenePix Pro 5.1 software (Axon Instruments Inc., Foster City, CA, USA). Spots were removed from further analysis if more than 70% of foreground pixels were below background intensity plus two S.D.s in both channels or if the difference between ratio of medians and regression ratio exceeded 20% in one of the channels. After removal of the low quality spots the remaining intensities were print tip lowess normalised in the R environment for statistical computing (18) with the aroma package (19) . To increase robustness considering the limited amount of patients, probe signals were required to be present in at least one technical replicate for each patient to be considered in the further analysis (6063 probes representing 4843 unique UniGene IDs). An exception was made in the comparison of aldosteronomas to all other samples where a maximum of five missing values were allowed in non-aldosteronoma specimens (12059 probes representing 8880 unique UniGene IDs). An empirical Bayes statistics (B-test) for ranking differentially expressed genes according to statistical significance was performed with the Limma package (20) . The criteria for statistical significance in the supplementary data files of differentially expressed genes were P!0.001 and log 2 fold changeO1. The P value is the Benjamini and Hochberg false discovery rate. Fischer's exact test was used for enrichment analysis of Gene Ontology (GO) terms and chromosomal location among the 1000 most significantly differentially expressed genes comparing malignant to non-malignant samples with a significance level of P!0.05. Clustering was performed with the stats and class packages.
Quantitative real time-PCR
In order to confirm the array findings we used a two step TaqMan quantitative real time-PCR (qRT-PCR) analysis. Synthesis of cDNA from total RNA was performed using the High-Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA, USA) on 0.5-1 mg of RNA from each sample. The reaction was carried out in a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems), under the conditions of an initial hold phase of 25 8C for 10 min, followed by 2 h at 37 8C. A 96-well plate was prepared for the TaqMan Gene Expression Assays (Applied Biosystems). Every well contained 12.5 ml of TaqMan Universal master mix, 1.25 ml of primer plus probe mix (Assays on Demand from Applied Biosystems), 6.25 ml of RNAse-free water and 5 ml of cDNA or previously prepared dilutions (reference curve). Dilutions were prepared for 1:10, 1:100, 1:1000 and 1:10 000. Every sample and control well was analysed in triplicates and the reference genes in duplicates according to manufacturer's recommendations. A non-template control well was used as negative control in every run. Wells were sealed with MicroAmp Optical caps. Plates were loaded into the ABI PRISM 7700 sequence detection system (Applied Biosystems). In order to select a reference gene for the quantification we used the TaqMan Human Endogenous Control Plate. This evaluates the expression of 11 selected reference genes, using qRT-PCR. The plate also features an internal positive control designed to detect the presence of PCR inhibitors in test samples. The explored genes were: 18S rRNA, acidic ribosomal protein, beta-actin, cyclophilin, GAPDH, phosphoglycerokinase, b2-microglobulin, beta-glucoronidase, hypoxanthine ribosyl transferase, transcription factor IID TATA binding protein and the transferrin receptor. The 18S rRNA gene was found to have the most stable expression levels among all samples and was thereby chosen as the reference gene to relate the transcript levels of the target genes. The genes analysed with qRT-PCR were: aldehyde dehydrogenase 1 family member A1 (ALDH1A1), insulin-like growth factor II precursor (IGF2), ubiquitin specific peptidase 4 (USP4) and ubiquitin fusion degradation protein 1 (UFD1L).
Western blot analysis
Frozen tissues were grounded into powder by mortaring on dry ice and subsequently dissolved by sonication in a buffer containing 50 mM Tris (pH 7.4), 5 mM MgCl 2 , 250 mM sucrose, 1 mM DTT and 1 mM ATP. The protein extracts were clarified by centrifugation and the lysates were snap-frozen in liquid nitrogen and kept frozen until use. For western blot analysis 20 mg protein/sample was fractionated on SDS-PAGE 4-12% gradient gels (Invitrogen), blotted on PVDF membranes, blocked in PBS supplemented with 5% skim milk and 0.1% Tween and probed with anti-Usp4 (C-term) antibody (Abgent Inc., San Diego, CA, USA), diluted 1:500. After subsequent washings and incubation with HRP-conjugated goat anti-rabbit serum (Amersham Biosciences), the blots were developed by ECL (GE Healthcare, Uppsala, Sweden). As a positive control for the Usp4 antibody we transfected human embryonic kidney 293T cells with a plasmid expressing USP4 in fusion with green fluorescent protein and harvested the cells for western blot analysis two days post-transfection.
Results
Classification with unsupervised methods
Principal component analysis, hierarchical clustering, k-means clustering and self-organising maps were applied to the filtered set of 6063 probes with expression values obtained in every tissue sample analysed. The carcinomas and the non-cancers clustered in separate groups with the exception of carcinoma 2931 (Fig. 1) . The discrepancy in gene expression is striking and the malignant behaviour seems to be congruent and outrule other inter-individual differences. Interestingly, the adenoma cluster fell into subgroups, with all incidentalomas represented in one group, all aldosteronomas in a second group and normal cortex and Cushing adenomas mixed into a third.
Differential gene expression in cancers
A t-test moderated with an empirical Bayesian statistics was applied to test for differential expression. When carcinomas, except case 2931, were compared to all other samples using the criteria for statistical significance described in Materials and methods, a significantly differential expression was observed for around 300 transcripts, Supplementary file 1A, which can be viewed online at http://www.eje-online.org/supplemental/. The 50 most significantly overexpressed and the 50 most significantly underexpressed transcripts are displayed in Fig. 2 . In Supplementary file 1B statistical data for all genes present in all samples is displayed. IGF2, a well established gene overexpressed in Figure 2 Expression profiles of the 50 most significantly up-regulated (top) and down-regulated (bottom) genes are displayed comparing cancer patients to non-cancer patients. The colour scale ranges from red to green analogous to over-to underexpression. In Supplementary files 1A and B, fold changes and P values are given.
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Enrichment analysis and GO classification of differentially expressed genes in cancers
An enrichment analysis of the chromosomal location of differentially expressed genes revealed that overexpression on chromosome 5 and underexpression on chromosome 2 and 1 were significant. To investigate which biological processes the differentially expressed genes were involved in, GO annotations were used. Enrichment analysis of the highest ranked differentially expressed transcripts according to statistical significance comparing carcinomas to all other samples showed that anti-apoptosis and cell cycle, were overrepresented among genes with altered transcript levels (Supplementary file 1C) . A subset of genes with GO annotation adhesion, mitosis or extracellular location is presented in Table 2 since these categories are of interest in the context of cancer development.
Verification by qRT-PCR
To confirm microarray results, four of the most significantly differentially expressed genes were analysed with qRT-PCR. qRT-PCR was performed for ALDH1A1, IGF2, USP4 and UFD1L. This confirmed IGF2 as significantly overexpressed and ALDH1A1 as significantly underexpressed in carcinomas (with the exception of sample 2931) compared to all other samples (Fig. 3) . The differences were too small and the variation was too high for USP4 and UFD1L to generate a significant difference. On average the up-regulation was 1.3-and 1.4-fold, respectively, in cancer versus non-cancer samples. The corresponding values for IGF2 was 144-fold up-regulation and 12-fold down-regulation of ALDH1A1. Ratios were calculated in a similar way for the array data by taking the average of the ratio for those genes in the cancer samples versus the reference RNA and then divide that with the corresponding ratio for the non-cancer samples. The corresponding fold over-expression for USP4 and UFD1L was 44 and 32 respectively. The corresponding values for IGF2 was 388-fold up-regulation and for ALDH1A1 11-fold down-regulation respectively.
USP4 protein expression is increased in adrenocortical carcinomas
The microarray data described here indicate a significant overexpression of the deubiquitinating enzyme USP4 (also known as UNP for ubiquitous nuclear protein) in adrenocortical carcinomas compared to adenomas. To test if the increased transcription correlates with elevated protein levels we prepared lysates from tumour biopsies and performed western blot analysis using an anti-USP4 antibody (Fig. 4) . A clear increase in a couple of close migrating bands corresponding to the expected size of endogenous USP4 was detected in the carcinoma samples as compared to normal reference. Smaller bands (w75 kDa) and additional weak bands reacting with the antibody may indicate potential splice variants or cleavage products of USP4.
Survival analysis and gene expression in cancer tumours
In order to examine if the survival of cancer patients were reflected in the gene expression patterns, cancer data were subject to hierarchical clustering using the entire filtered probe set where each gene profile had been normalised to the same range. The resulting two subclusters had different outcomes; one cluster contained patients with short survival (!9 months) and the other patients with long survival (O67 months) suggesting that gene expression profiles may be used for prediction of survival. In Fig. 5A , the dendogram based on the entire probe set is displayed together with the gene expression profiles of 30 up-and 30 down-regulated genes. The Kaplan-Meier survival curves of the two subclusters are shown in Fig. 5B .
Differential expression associated with hormonal activity of benign tumours
The benign tumour sample set consisted of five Cushing, four aldosteronomas and eight non-hormonal overproducing incidentalomas. Comparing each subtype to the other samples we could detect 11 genes with expression levels connected to aldosteronomas using the statistical criteria for differential expression described in Materials and methods (Table 3 ). In Supplementary file 2A, which can be viewed online at http://www.eje-online.org/supplemental/, data for all probes is shown. Differentially expressed genes were not identified for the other subtypes. Among the dysregulated genes were, vascular endothelial growth factor B (VEGFB) and oxysterol binding protein (OSBP).
Comparison of aldosteronomas versus incidentalomas revealed several significantly dysregulated genes as detailed in Supplementary file 2B. Mevalonate kinase (MVK) was up-regulated in aldosteronomas as well as peroxiredoxin 5 (PRDX5), while tumour necrosis factor receptor super family 25 (TNFRSF25) was downregulated (Supplementary files 2B and C).
Discussion
It is important to elucidate the relation and differences between benign and malignant adrenocortical tumours, both in terms of obtaining an increased understanding for the underlying molecular mechanisms as well as to enhance possibilities for correct diagnosis and prognosis for the individual patient. Previous studies have demonstrated that adrenocortical carcinomas display specific and more numerous chromosomal and/or genetic alterations than adenomas (4, 5) , which could suggest a characteristic malignant genotype. In a previous study we showed that malignant gene expression profiles are distinguishable from those of benign tumours (16) . In this extended study we also included normal adrenal cortex to ascertain that the characteristics that separated cancers from benign tumours were associated with malignancy and not present in normal adrenocortex. We found potentially useful expression profiles which could enable differentiation between carcinomas and non-malignant adrenocortical tissue (normal adrenocortex and adenomas), and furthermore between different subclasses of adenomas. We could also show that in the malignant group tumours from patients with long survival and tumours from patients with short survival fell into two separate cluster groups. The IGF signalling pathway plays a major role in several cancer forms and is interesting considering development of therapeutics and as a diagnostic approach. IGF2 was up-regulated in adrenocortical carcinomas in this study as in previous published gene expression profiling studies on adrenocortical tumours (21) (22) (23) (24) (25) . Elevated expression levels of IGF2 has been detected in several other cancer forms (26) (27) (28) . In a study of ovarian cancer, expression levels of IGF2 have been demonstrated to be inversely correlated to survival (29) . Serum levels of IGF2 have been proven to have biomarker potential for tumour staging of prostate cancer as a complement to PSA (30) . IGF2 is thus a Figure 4 Usp4 protein levels are increased in adrenocortical carcinomas compared with adenomas. Western blot analysis using an anti-USP4 antibody showing increased expression of USP4 protein in adrenocortical carcinomas as compared to adenomas. Underlined are paired samples of tumour (T) and normal adrenal cortex (N) from the same patient. An additional smaller product reacting with the USP4 antibody shows increased expression in carcinomas (asterisk).
relatively general cancer marker but still has the potential to become very useful to distinguish adrenocortical adenomas from carcinomas.
Several of the up-regulated genes in carcinomas, such as the deubiquitinating enzymes USP4 and USP38, the ubiquitin conjugating enzyme UBE2C, the small ubiquitin-like modifier SUMO-1 and UFD1L are involved in the ubiquitination pathway (Fig. 2) . Posttranslational modification by ubiquitin has emerged as a major regulatory event that is essential for cellular processes such as cell cycle progression, signal transduction, transcriptional regulation, and apoptosis (31) . USP4, which was among the most up-regulated genes is an enzyme of yet unclear function, however, its deregulation has previously been linked to cancer and USP4 has been ascribed oncogenic (32, 33) as well as having tumour suppressor functions (34) indicating that it may be a multifunctional protein. USP4 has previously been reported to interact with the retinoblastoma tumour suppressor, pRb, the pocket proteins, p107 and p130 (35, 36) , the ubiquitin ligase Ro52 (37) and the transmembrane G-coupled adenosine 2A receptor for which it has been suggested to function to relax the endoplasmic reticulum quality control mechanisms, resulting in increased cell surface expression of the receptor (38) . The role of USP4 in adrenocortical carcinomas is however, still unexplored. UBE2C (also known as UbcH10) is a ubiquitin conjugating enzyme involved in cell cycle regulation (39) and its over expression has been suggested to be a valid indicator of human cancers of various tissue origin (40) (41) (42) .
Differentially expressed genes in carcinomas showed overrepresentation for location on chromosome 5 among genes up-regulated in cancer, while downregulated genes were enriched for chromosome 1 and 2. These observations overlap with those made with CGH showing gains on chromosome 5 and losses on chromosome 2 in adrenocortical cancers (4) .
As previously mentioned, we found an interesting cancer case (ID 2931), that surprisingly clustered with normal cortex and adenomas in the unsupervised hierarchical clustering (Fig. 1) . This patient had no metastasis at the time of surgery but received mitotane as adjuvant chemotherapy. The patient is still alive 67 months after surgery without any evidence of residual disease or metastasis. The tumour showed low proliferation with MIB-1/Ki-67, !3% of activity. Interestingly, this case also showed gene expression levels similar to the 'normal or adenoma' pattern in the qRT-PCR for IGF2 and ALDH1A1 (Fig. 3) . In addition, two specific genes (PINK1 and BUB1B) were selected as biomarkers, which in combination could be used for prediction of survival. In our study two subclusters with different survival outcomes could be observed as well. Due to the limited sample set size, we chose not to select any specific markers based on these. However, we could confirm that PINK1 and BUB1B also could be used as predictors for survival in our cases (data not shown) although BUB3 was a better predictor than BUB1B. A weakness of the analysis in our study to take into consideration is that all diseased patients but one (372) are females.
Regarding tumours with different hormonal activity, differences in expression patterns of genes related to steroid hormone synthesis are of special interest. Several interesting genes involved in intermediate metabolism were present on the array, such as the oxysterol binding protein (OSBP) which was found to be up-regulated in aldosteronomas. This gene is involved in sterol transport from lysosomes to the nucleus, down-regulating the expression of other genes such as LDL-receptor, HMG-CoA reductase and HMG synthetase, involved in lipid synthesis. An early enzyme in steroid synthesis is mevalonate kinase (MVK), which was up-regulated in aldosteronomas compared to incidentalomas. Besides genes directly involved in hormonal metabolism, many other genes were found to be differentially expressed in aldosteronomas, among these VEGFB, adenosine deaminase (ADA), inositol 1,3,4-triphosphate 5/6 kinase (ITPK1), ubiquitin thiolesterase 1 (UCHL1), tumour necrosis factor receptor super family member 25 (TNFRSF25), and the V-abl Abelson murine leukaemia viral oncogene homolog 1 (ABL1; Supplementary file 2A and B) .
Conclusions
Through the transcriptional profiling, different subtypes of functional adenomas and carcinomas may be distinguished based on their specific molecular signature. This study confirms and extends the findings of previous studies in this respect. Our utilisation of a whole genome cDNA microarray may serve as a complement to gene expression data retrieved with Affymetrix high density microarrays and cDNA macroarrays. Further investigation of the relevance of genes with subtype specific differential expression has the potential to eventually lead to clinical breakthroughs together with the findings of the larger studies recently published. Genes with expression levels connected to malignancy, survival and hormonal activity were detected in our data. Identification of these differentially expressed genes may enhance our understanding of the molecular biology of adrenocortical tumour development and its functional phenotype, and aid in creating new diagnostic and prognostic tools.
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